BioSpace News Archive

Arix Bioscience plc is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).

DCCR treatment resulted in statistically significant decreases in body fat in subjects with Prader-Willi Syndrome

New Regenstrief and IU methodology identifies, swiftly implements evidence-based solutions

The U.S. Department of Commerce announced today that the 2018 Malcolm Baldrige National Quality Award will be given to two educational institutions, an organ donor group, a hospital and a project management firm.

How can a doctor predict the treatment outcome of an individual patient? Traditionally, the effectiveness of medical treatments is studied by randomised trials where patients are randomly divided into two groups: one of the groups is given treatment, and the other a placebo.

NOXXON ends the use of variable rate equity financing with Yorkville

New research published in The Journal of Physiology presents a breakthrough in the treatment of Restless Legs Syndrome (RLS).

Four ongoing clinical trial programs

Highlights potential role of both complement and leukotriene pathways in a therapeutic mouse model of rheumatoid arthritis (RA)

Tulane researchers James McLachlan and Lisa Morici explain how nanoparticles shed from bacteria can be used in future vaccines to illicit a more potent immune response than existing technologies. The project aims to design a more effective vaccine against pertussis.